Department of Endocrinology and Metabolism, Fourth People's Hospital of Shenyang, Shenyang, China.
Department of Endocrinology and Metabolism, First Affiliated Hospital of Soochow University, Suzhou, China.
Front Endocrinol (Lausanne). 2022 Feb 1;12:741748. doi: 10.3389/fendo.2021.741748. eCollection 2021.
Benign prostatic hyperplasia (BPH) is a disease that causes lower urinary tract symptoms (LUTS), which are the most common urological problem in approximately one-third of the male population aged over 50 years. Some studies have suggested that diabetes may be a risk factor for the development of BPH. However, whether diabetes aggravates the LUTS of BPH patients is still controversial.
To investigate the impact of diabetes mellitus on LUTS in BPH patients.
A literature search was conducted using Web of Science, Embase, PubMed, and China National Knowledge Infrastructure literature databases. This meta-analysis was registered in PROSPERO (registration number: CRD 42020200794). Fixed- or random-effects models were used for analysis according to heterogeneity. The results of the systematic analysis are presented as weighted mean difference (WMD) with the corresponding 95% confidence intervals (CI).
In total, 1308 studies were retrieved from databases and 18 articles comprising 1685 cases and 4653 controls were selected for meta-analysis. The results of the meta-analysis showed that the International Prostate Symptom Score (IPSS) value and prostate volume of BPH patients with diabetes was significantly higher than that of BPH patients without diabetes.
This systematic review is the first to evaluate the impact of diabetes mellitus on LUTS in BPH patients. The results of our meta-analysis support the hypothesis that LUTS in BPH patients is increased in patients with diabetes mellitus compared with controls, which suggests that physicians should pay more attention to BPH patients with diabetes mellitus.
PROSPERO [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=200794], identifier CRD 42020200794.
良性前列腺增生(BPH)是一种导致下尿路症状(LUTS)的疾病,这是大约三分之一年龄在 50 岁以上的男性中最常见的泌尿科问题。一些研究表明,糖尿病可能是 BPH 发展的一个危险因素。然而,糖尿病是否会加重 BPH 患者的 LUTS 仍存在争议。
探讨糖尿病对 BPH 患者 LUTS 的影响。
使用 Web of Science、Embase、PubMed 和中国国家知识基础设施文献数据库进行文献检索。本荟萃分析在 PROSPERO(注册号:CRD42020200794)中进行注册。根据异质性,采用固定效应或随机效应模型进行分析。系统分析的结果以加权均数差(WMD)及其相应的 95%置信区间(CI)表示。
从数据库中检索到 1308 项研究,最终纳入 18 项研究,共包含 1685 例病例和 4653 例对照,进行荟萃分析。荟萃分析结果显示,糖尿病 BPH 患者的国际前列腺症状评分(IPSS)值和前列腺体积明显高于非糖尿病 BPH 患者。
这是第一项评估糖尿病对 BPH 患者 LUTS 影响的系统评价。我们的荟萃分析结果支持糖尿病患者 LUTS 比对照组增加的假设,这提示医生应更加关注患有糖尿病的 BPH 患者。
PROSPERO [https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=200794],注册号 CRD42020200794。